Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Mechanismen des Nutzens der IL4RA-Hemmung bei durch Aspirin verschlimmerter Atemwegserkrankung (MARINER)

21. Oktober 2026 aktualisiert von: Tanya Laidlaw, MD, Brigham and Women's Hospital

Mechanismen des Nutzens der IL4RA-Hemmung bei durch Aspirin verschlimmerter Atemwegserkrankung: MARINER

The overall aim of the study is to determine the clinical efficacy and mechanisms of action of anti-IL-4a (dupilumab) as treatment for patients with Chronic Rhinosinusitis with Nasal Polyposis (CRSwNP) and Aspirin-Exacerbated Respiratory Disease (AERD).

Studienübersicht

Detaillierte Beschreibung

The protocol involves an 8-week study of dupilumab in patients with CRSwNP and/or AERD. Participants will have 4 total doses of dupilumab administered, with each dose administered every 2 weeks. There will be full clinical assessments and biospecimen collections at Baseline (Visit 1), Week 2 (Visit 2), and Week 8 (Visit 3).

Studientyp

Interventionell

Einschreibung (Tatsächlich)

17

Phase

  • Phase 2

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienorte

    • Massachusetts
      • Boston, Massachusetts, Vereinigte Staaten, 02115
        • Brigham and Women's Hospital

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

18 Jahre bis 75 Jahre (Erwachsene, Älterer Erwachsener)

Akzeptiert gesunde Freiwillige

Nein

Studienberechtigte Geschlechter

Alle

Beschreibung

Key Inclusion Criteria:

  1. History of AERD, defined as meeting the diagnostic triad with:

    1. History of physician-diagnosed asthma and
    2. History of physician-diagnosed nasal polyposis and
    3. History of pathognomonic reactions to aspirin or other nonselective COX inhibitors.
  2. Visible nasal polyps bilaterally on otoscope physical exam at the time of screening.

  3. Evidence of sense of smell impairment, with a University of Pennsylvania Smell Identification Test (UPSIT) score of <34.

  4. Stable asthma (no glucocorticoid burst for at least 4 weeks prior to Visit 1, and no hospitalizations or ER visits for asthma for at least the prior 3 months).

  5. Consistent (daily) use of an intranasal steroid for at least 4 weeks prior to Screening.

  6. No current smoking (not more than one instance of smoking in the last 3 months).

  7. For females: Practicing FDA-approved methods of birth control for the duration of the study. Female participants of childbearing potential must have a negative pregnancy test upon study entry.

Key Exclusion Criteria:

  1. Use of investigational drugs within 12 weeks of Screening.
  2. Use of any biologic agent within 4 months prior to Screening.
  3. Use of systemic (enteral or injected) glucocorticoids within 4 weeks prior to Screening.
  4. History of any sinonasal surgery within 4 months prior to Screening
  5. Current use of zileuton
  6. Current use of high-dose aspirin therapy (no more than 325 mg aspirin per day will be allowed)
  7. Pregnant, nursing, or planning to become pregnant

Note: Other inclusion and exclusion criteria apply.

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Behandlung
  • Zuteilung: N / A
  • Interventionsmodell: Einzelgruppenzuweisung
  • Maskierung: Keine (Offenes Etikett)

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Experimental: Dupilumab

Subjects will receive dupilumab (300mg every-other-week for 8 weeks).

8-week trial of dupilumab (an anti-IL-4a) in patients with AERD.

Andere Namen:
  • Dupilumab Fertigspritze [Dupixent]

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Nasal Fluid Levels of LTE4
Zeitfenster: At Week 8 (Visit 3)

The nasal fluid levels of LTE4 will be measured at week 8 and will serve as a surrogate biomarker of respiratory mast cell activation or burden.

At Week 8 (Visit 3)

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Nasal Fluid Levels of Albumin
Zeitfenster: At Week 8 (Visit 3)

The nasal fluid levels of albumin will be measured at week 8 and serve as a surrogate biomarker of nasal epithelial cell integrity.

At Week 8 (Visit 3)
Sense of Smell - University of Pennsylvania Smell Identification Test (UPSIT)
Zeitfenster: At Week 8 (Visit 3)

Patients' sense of smell will be assessed at week 8 using the UPSIT. The UPSIT scale goes from 0 to 40, with 0 being worse (no scents identified) and 40 being best (all scents identified)

At Week 8 (Visit 3)
Rhinoscopic Total Polyp Score (TPS)
Zeitfenster: At Week 8 (Visit 3)

The extent of patients' nasal polyps will be assessed at week 8 using a TPS. The TPS scale goes from 0 (no polyps) to 8 (large polyps bilaterally), with 0 being best and 8 being worst.

At Week 8 (Visit 3)
Peak Nasal Inspiratory Flow (PNIF)
Zeitfenster: At Week 8 (Visit 3)

Patients' nasal congestion will be assessed at week 8 by a PNIF. PNIF goes from 0 mL (no airflow) to 500 mL of airflow, with 0 being worst.

At Week 8 (Visit 3)
Quality of Life - 22-Item Sino-Nasal Outcome Test (SNOT-22)
Zeitfenster: At Week 8 (Visit 3)

Quality of life will be assessed at week 8 with a SNOT-22. For the SNOT-22, the scores range from 0 (no symptoms, excellent disease control) to 110 (maximum sinus symptoms, poor disease control).

At Week 8 (Visit 3)
Lung Function - Forced Expiratory Volume 1 (FEV1)
Zeitfenster: At Week 8 (Visit 3)

Patients' lung function will be assessed at week 8 with an FEV1.

At Week 8 (Visit 3)
Asthma Control - Asthma Control Questionnaire-6 (ACQ-6)
Zeitfenster: At Week 8 (Visit 3)

Asthma control will be measured at week 8 with an ACQ-6. For the ACQ-6, scores ranging from 0 (well-controlled) to 6 (extremely poorly-controlled). A lower score indicates better asthma control.

At Week 8 (Visit 3)
Number of Treatment-related Adverse Events (AEs) and Serious Adverse Events (SAEs) Leading to Study Drug Discontinuation
Zeitfenster: At Week 8 (Visit 3)

Safety will be measured by the number of treatment-related AEs and SAEs leading to dupilumab discontinuation.

At Week 8 (Visit 3)

Andere Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Change in Sense of Smell - University of Pennsylvania Smell Identification Test (UPSIT)
Zeitfenster: 2 weeks (between Visit 1 and Visit 2) and 8 weeks (between Visit 1 and Visit 3)

Change from Visit 1 to Visit 2 and from Visit 1 to Visit 3 in UPSIT. The UPSIT scale goes from 0 to 40, with 0 being worse (no scents identified) and 40 being best (all scents identified)

2 weeks (between Visit 1 and Visit 2) and 8 weeks (between Visit 1 and Visit 3)
Change in Rhinoscopic Total Polyp Score (TPS)
Zeitfenster: 2 weeks (between Visit 1 and Visit 2) and 8 weeks (between Visit 1 and Visit 3)

Change from Visit 1 to Visit 2 and from Visit 1 to Visit 3 in TPS. The TPS scale goes from 0 (no polyps) to 8 (large polyps bilaterally), with 0 being best and 8 being worst.

2 weeks (between Visit 1 and Visit 2) and 8 weeks (between Visit 1 and Visit 3)
Change in Peak Nasal Inspiratory Flow (PNIF)
Zeitfenster: 2 weeks (between Visit 1 and Visit 2) and 8 weeks (between Visit 1 and Visit 3)

Change from Visit 1 to Visit 2 and from Visit 1 to Visit 3 in PNIF. PNIF goes from 0 mL (no airflow) to 500 mL of airflow, with 0 being worst.

2 weeks (between Visit 1 and Visit 2) and 8 weeks (between Visit 1 and Visit 3)
Change in 22-Item Sino-Nasal Outcome Test (SNOT-22)
Zeitfenster: 2 weeks (between Visit 1 and Visit 2) and 8 weeks (between Visit 1 and Visit 3)

Change from Visit 1 to Visit 2 and from Visit 1 to Visit 3 in SNOT-22. For the SNOT-22, the scores range from 0 (no symptoms, excellent disease control) to 110 (maximum sinus symptoms, poor disease control).

2 weeks (between Visit 1 and Visit 2) and 8 weeks (between Visit 1 and Visit 3)
Change in Lung Function - Forced Expiratory Volume 1 (FEV1)
Zeitfenster: 2 weeks (between Visit 1 and Visit 2) and 8 weeks (between Visit 1 and Visit 3)

Change from Visit 1 to Visit 2 and from Visit 1 to Visit 3 in FEV1.

2 weeks (between Visit 1 and Visit 2) and 8 weeks (between Visit 1 and Visit 3)
Change in Asthma Control - Asthma Control Questionnaire-6 (ACQ-6)
Zeitfenster: 2 weeks (between Visit 1 and Visit 2) and 8 weeks (between Visit 1 and Visit 3)

Change from Visit 1 to Visit 2 and from Visit 1 to Visit 3 in ACQ-6. For the ACQ-6, scores ranging from 0 (well-controlled) to 6 (extremely poorly-controlled). A lower score indicates better asthma control.

2 weeks (between Visit 1 and Visit 2) and 8 weeks (between Visit 1 and Visit 3)
Change in Nasal Fluid Levels of Eicosanoids
Zeitfenster: weeks (between Visit 1 and Visit 2) and 8 weeks (between Visit 1 and Visit 3)

Change from Visit 1 to Visit 2 and from Visit 1 to Visit 3 in nasal fluid eicosanoid levels.

weeks (between Visit 1 and Visit 2) and 8 weeks (between Visit 1 and Visit 3)
Change in Nasal Fluid Levels of Albumin
Zeitfenster: 2 weeks (between Visit 1 and Visit 2) and 8 weeks (between Visit 1 and Visit 3)

Change from Visit 1 to Visit 2 and from Visit 1 to Visit 3 in nasal fluid albumin levels.

2 weeks (between Visit 1 and Visit 2) and 8 weeks (between Visit 1 and Visit 3)
Change in Urinary Levels of Eicosanoids
Zeitfenster: 2 weeks (between Visit 1 and Visit 2) and 8 weeks (between Visit 1 and Visit 3)

Change from Visit 1 to Visit 2 and from Visit 1 to Visit 3 in urinary eicosanoid levels.

2 weeks (between Visit 1 and Visit 2) and 8 weeks (between Visit 1 and Visit 3)
Change in Serum Tryptase
Zeitfenster: 2 weeks (between Visit 1 and Visit 2) and 8 weeks (between Visit 1 and Visit 3)

Change from Visit 1 to Visit 2 and from Visit 1 to Visit 3 in serum tryptase levels.

2 weeks (between Visit 1 and Visit 2) and 8 weeks (between Visit 1 and Visit 3)
Change in IgE Levels
Zeitfenster: 2 weeks (between Visit 1 and Visit 2) and 8 weeks (between Visit 1 and Visit 3)

Change from Visit 1 to Visit 2 and from Visit 1 to Visit 3 in nasal fluid and plasma levels of IgE.

2 weeks (between Visit 1 and Visit 2) and 8 weeks (between Visit 1 and Visit 3)
Change in Eosinophilic Cationic Protein (ECP)
Zeitfenster: 2 weeks (between Visit 1 and Visit 2) and 8 weeks (between Visit 1 and Visit 3)

Change from Visit 1 to Visit 2 and from Visit 1 to Visit 3 in nasal fluid levels of ECP.

2 weeks (between Visit 1 and Visit 2) and 8 weeks (between Visit 1 and Visit 3)

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Ermittler

  • Hauptermittler: Tanya M Laidlaw, MD, Brigham and Women's Hospital

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Tatsächlich)

1. August 2023

Primärer Abschluss (Tatsächlich)

30. April 2026

Studienabschluss (Geschätzt)

30. Dezember 2026

Studienanmeldedaten

Zuerst eingereicht

7. Oktober 2022

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

7. Oktober 2022

Zuerst gepostet (Tatsächlich)

12. Oktober 2022

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

13. November 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

21. Oktober 2026

Zuletzt verifiziert

1. August 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Plan für individuelle Teilnehmerdaten (IPD)

Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?

NEIN

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Ja

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Produkt, das in den USA hergestellt und aus den USA exportiert wird

Ja

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .

Abonnieren